Integrating Ci-Ca therapy in your clinical practice.
Many critically ill patients in intensive care units (ICUs) are suffering from multi-organ failure and they depend on reliable application of organ support therapies.13
The multiFiltratePRO offers a wide range of therapeutic applications, mostly in intensive care, such as:
* Legal manufacturer of multiECCO2R is EUROSETS S.r.l., Italy. Fresenius Medical Care Deutschland GmbH is a distributor of multiECCO2R in selected countries.
Explore the multiFiltratePRO
1 Weidhase L et al. Plos One 2019; 14:e0215823
2 Eichhorn T et al. Blood Purif 2017; 44:260-266
3 Weidhase et al. Crit Care 2020; 24:644
4 Hafner S et al. J Intensive Care 2015; 3:35
5 Bianchi NA et al. Blood Purif 2020; 49:567-575
6 Kalb R et al. Ther Apher Dial 2013; 17:202-212
7 Zarbock A et al. JAMA 2020;324:1629-1639
8 Morgera et al. Crit Care Med 2009;37:2018-2024
9 Slowinski T et al. Crit Care 2015; 19:349
10 Houllé-Veyssière et al. Intensive Crit Care Nurs 2016; 36:35-41
11 Link A et al. Crit Care 2012; 16:R97
12 Huguet M et al. Int J Artif Organs 2017; 40:676-682
13 ICNARC. Case Mix Programme Summary Statistics 2019-20, www.icnarc.org/Our-Audit/Audits/Cmp/Reports/Summary-Statistics, accessed April 2021